(Registrant’s telephone number including area code) i336-i229-1127
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
i☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act.
Title of Each Class Trading Symbol Name of exchange on which registered
iCommon Stock , $0.10 par valueiLHiNew
York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Laboratory Corporation of AmericaHoldings (“Labcorp”) today announced that on March 25, 2021, Labcorp’s Board of Directors (the “Board”) appointed Kathryn E. Wengel as a member of the Board, effective immediately. Ms. Wengel will be entitled to receive compensation for her service on the Board consistent with Labcorp’s director compensation program, as described in Labcorp's most recent proxy statement, filed with the Securities and Exchange Commission on April 1, 2020.
Ms.
Wengel currently serves as Executive Vice President and Chief Global Supply Chain Officer of Johnson & Johnson. In her over 30 years of experience at Johnson & Johnson, Ms. Wengel has served in various positions of increasing responsibility across the enterprise, including as the Worldwide Vice President and Chief Supply Chain Officer, Chief Quality Officer, Vice President of Quality & Compliance, and Worldwide Vice President of Environment, Health & Safety.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
